Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01298037 · ClinicalTrials.gov registry record
HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B
A clinical trial of Hepatitis B, sponsored by University of Pennsylvania.
- Active
- Registry status
- 201
- Enrollment target
- 12
- Study locations
NCT01298037: Active study of Hepatitis B, sponsored by University of Pennsylvania.
NCT01298037 is a study of Hepatitis B that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 201 participants, below the 1,622-participant average among 32 other Hepatitis B trials with a reported enrollment target (88% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01298037, a study of Hepatitis B, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 201 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is an ancillary to the NIDDK-sponsored Hepatitis B Research Network (HBRN) Study Cohort Study NCT01263587. This study will examine the balance between immune regulatory and effector responses in hepatitis B-infected participants enrolled in the HBRN study (NCT01263587).
Primary Outcome
Immune regulatory and effector responses relative to HBV DNA, ALT and clinical outcome. HBV-specific lymphoproliferative, IFN-gamma and IL 10 responses, T cell activation and costimulatory markers (PD1, CTLA4, CD28, CD127), FoxP3+ Treg frequency, and NK frequency and expression of activating/inhibitory receptors and Dendritic cell frequency.
Conditions Studied
Study Locations (12)
California
- California Pacific Medical Center - San Francisco
- University of California San Francisco Medical Center - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Minnesota
- University of Minnesota - Plymouth
- Mayo Clinic Rochester - Rochester
Washington
- Virginia Mason Medical Center - Seattle
- Harborview Medical Center - Seattle
North Carolina
- University of North Carolina - Chapel Hill
Texas
- University of Texas Southwestern - Dallas
Virginia
- Virginia Commonwealth University - Richmond
Ontario
- University of Toronto - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2011-02-01 |
| Est. Completion | 2026-12-01 |
What the registry record for NCT01298037 still lists
NCT01298037 is an observational study that tracks outcomes without assigning an intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, below the 1,622-participant average among 32 other Hepatitis B trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Hepatitis B appearing as the primary indexed condition, and to 0 interventions.
NCT01298037 lists 12 locations in 8 states (California, Massachusetts, Minnesota).
Frequently Asked Questions
What is clinical trial NCT01298037 about?
NCT01298037 is a clinical study titled "HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B". This is an ancillary to the NIDDK-sponsored Hepatitis B Research Network (HBRN) Study Cohort Study NCT01263587. This study will examine the balance between immune regulatory and effector responses in hepatitis B-infected participants enrolled in the HBRN study (NCT01263587).
What is the current status of trial NCT01298037?
This trial is currently active not recruiting. The enrollment target is 201 participants. The study started on 2011-02-01. Estimated completion is 2026-12-01.
What conditions does trial NCT01298037 study?
This clinical trial studies the following conditions: Hepatitis B.
Who is sponsoring clinical trial NCT01298037?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01298037 being conducted?
This trial has 12 study locations across California, Massachusetts, Minnesota, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01298037's enrollment target sits among peer trials
201 15th of 32 higher than 18 of 32 other Hepatitis B trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis B trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Patients With Liver Disease
RECRUITING
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
-
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
RECRUITING · Phase 2
-
National Liver Cancer Screening Trial
RECRUITING · Phase 4
-
HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers
RECRUITING · Phase 4
-
A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI